14
Nov
2005
VentureScape Through 3Q05
Posted in Uncategorized
Who are you going to believe? Is it the VentureOne survey indicating 27 firms have raised $5.91 billion in 3Q05, up from 26 funds closing $5.11 billion in the same period last year, or are you going to buy the National Venture Capital Association data indicating 45 firms raising $5.39 billion in the quarter, likewise [...]
04
Nov
2005
FBBi — The Business of Science
Posted in Uncategorized
Coming soon to a BioWest 2005 conference near you…
The Fitzsimons BioBusiness Incubator (FBBi) is dedicated to promoting the growth and success of bioscience businesses in Colorado, with a special emphasis on forming a bioscience cluster at Fitzsimons.
FBBi connects ideas, technology, and people to deliver targeted assistance to start-up companies and entrepreneurs. We unite industry experts, [...]
07
Oct
2005
Brotica: A Chemical Attraction
Posted in Uncategorized
Brotica, Inc. was established in 2002 by a team of six researchers from Colorado State University. Brotica’s objective is to develop environmentally friendly, non-chemical products that fill gaps that exist in modern insect control strategies. Currently, Brotica is developing, manufacturing and selling Interval33™, a patented termite attractant that can be used in conjunction [...]
04
Oct
2005
ApopLogic Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products that target unique apoptotic cell death pathways found in tumor cells and proliferating lymphocytes. The Company was formed in the summer of 2005 to capitalize on the intellectual property of its Scientific Founders, Richard C. Duke and Donald [...]
02
Oct
2005
In 2002, CU Professors Bob Sievers and John Carpenter, together with Dr. Brian Quinn, founded Aktiv-Dry, LLC. The purpose of the company is to commercialize the use of supercritical carbon dioxide to form micro- and nano-scale particles of thermally sensitive compounds. The pharmaceutical industry is creating a demand for fine dry powders of [...]
25
Sep
2005
GlobeImmune, Inc. recently announced the successful closing of a Series B stock financing raising $34.3 million, to enable continued development of their two lead Tarmogen™ products in the oncology and infectious disease segments.
The Series B was led by Lilly Ventures along with Medica Venture Partner, Adams Street Partners, Biogen Idec, Inc., Genentech, Inc., Partners Healthcare [...]
17
Aug
2005
Denver based Ceragenix Pharmaceuticals (NASDAQ: CGXP.OB), led in part by the research of Chief Scientific Officer Dr. Peter Elias, (UCSF), today was awarded a $1.2M NIH grant to examine the skins barrier function as it relates to eczema vaccinatum, a potentially fatal complication of smallpox vaccination in persons who have or have had eczema. In [...]
15
Jun
2005
Valuation…That Slippery Slope
Posted in Uncategorized
Thank you to Luis at A2VC for providing this interesting tid bit of data. This comes to us from PWC-Thomson Venture Economics-NVCA-Money Tree Survey. Here we are looking at VC valuations for early stage companies before investment and the investment amount. So a company appears to fall in the pre-money valuation range of $8 to [...]
Life Science Deal Flow PARTNERS
-
